Results 261 to 270 of about 87,967 (330)

Meta-Analysis of the Association Between Phosphodiesterase Inhibitors (PDE5Is) and Risk of Melanoma. [PDF]

J Natl Cancer Inst, 2017
Loeb S, Ventimiglia E, Salonia A, Folkvaljon Y, Stattin P.   +4 more
europepmc   +1 more source

Photoreceptor degeneration has heterogeneous effects on functional retinal ganglion cell types

The Journal of Physiology, EarlyView.
Abstract figure legend Photoreceptor loss has heterogeneous effects on functional retinal ganglion cell (RGC) types. A, illustrations of cross‐sections of rd10 retinae at different time points during degeneration. Left: P30, rod degeneration has commenced, cones are still unaffected.
Nadine Dyszkant, Jonathan Oesterle, Yongrong Qiu, Merle Harrer, Timm Schubert, Dominic Gonschorek, Thomas Euler   +6 more
wiley   +1 more source

Use of phosphodiesterase inhibitors and prevalence of self-reported glaucoma in the United States. [PDF]

PLoS One, 2017
Chen SP, Singh K, Lin SC.
europepmc   +1 more source

Computational modelling of cardiac fibroblast signalling reveals a key role for Ca2+ in driving atrial fibrillation‐associated fibrosis

The Journal of Physiology, EarlyView.
Abstract figure legend A pre‐existing fibroblast signalling model was enhanced by integrating atrial‐specific components and reactions linked to atrial fibrosis and atrial fibrillation (AF). The analysis highlights the central role of Ca2⁺ signalling in driving profibrotic responses to AF‐relevant stimuli, angiotensin‐II and transforming growth factor ...
Najme Khorasani, Haibo Ni, Jeffrey J Saucerman, Dobromir Dobrev, Stefano Morotti, Eleonora Grandi   +5 more
wiley   +1 more source

Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast. [PDF]

BioDrugs, 2015
Gooderham M, Papp K.
europepmc   +1 more source

Primary Progressive Multiple Sclerosis: New Therapeutic Approaches

Neuropsychopharmacology Reports, Volume 45, Issue 3, September 2025.
Primary progressive MS affects 10%–15% of MS patients, causing irreversible neurological impairment. Drugs like ocrelizumab show promise, while high‐dose biotin, simvastatin, and coenzyme Q10 are under investigation. Gene therapy and stem cell treatments also show potential.
Morteza Rajabi, Sajjad Shafaeibajestan, Sevda Asadpour, Ghazal Alyari, Niloofar Taei, Moein Kohkalani, Ramin Raoufinia, Hamed Afarande, Ehsan Saburi   +8 more
wiley   +1 more source

AN ISOENZYME-SELECTIVE INHIBITOR OF PHOSPHODIESTERASE 4 AND 1, KF19514, MAY BE USEFUL IN THE TREATMENT OF SYSTEMIC ANAPHYLAXIS

, 1999
Naoki Hasome, Hiromasa Mitsuhata, Jin Saitoh, Haruhiko Takeuchi, Reiju Shimizu   +4 more
openalex   +1 more source

Multi‐Target Drug Design in Alzheimer's Disease Treatment: Emerging Technologies, Advantages, Challenges, and Limitations

Pharmacology Research &Perspectives, Volume 13, Issue 4, August 2025.
ABSTRACT Alzheimer's disease (AD) is a complex and multifactorial neurodegenerative disorder, recognized as the most prevalent form of dementia. It is characterized by multiple pathological processes, including amyloid‐beta accumulation, neurofibrillary tangles, and neuroinflammation. The therapeutic efficacy of traditional single‐target drugs has been
Md Saad Hossain, Md Hamed Hussain
wiley   +1 more source

Use of sildenafil or other phosphodiesterase inhibitors and risk of melanoma. [PDF]

Br J Cancer, 2016
Pottegård A, Schmidt SA, Olesen AB, Achacoso N, Van Den Eeden SK, Hallas J, Sørensen HT, Friis S, Habel LA.   +8 more
europepmc   +1 more source

Coronary Microvascular Dysfunction in Ischaemic Heart Disease: Lessons From Large Animal Models

Basic &Clinical Pharmacology &Toxicology, Volume 137, Issue 2, August 2025.
ABSTRACT The coronary microvasculature is principally responsible for matching coronary blood flow to myocardial demand of oxygen and nutrients. Short‐term control of coronary blood flow is achieved via alterations in coronary microvascular tone, whereas long‐term control of coronary flow also involves remodelling of the coronary microvasculature ...
Oana Sorop, J. van de Wouw, Daphne Merkus, Dirk J. Duncker   +3 more
wiley   +1 more source